Clinical Scorecard: Analysis of Competing Risks for Recurrence Following Nephron-Sparing Approaches in Renal Cell Carcinoma

At a Glance

Key Highlights

• Local recurrence occurs in approximately 3% after partial nephrectomy and 14% after ablative therapy.
• Repeated ablation is preferred after ablative therapy failure, but optimal salvage treatment remains undefined.
• Local recurrence typically develops within 20–36 months post-treatment and may be managed surgically or with ablative therapy if no systemic progression.

Guideline-Based Recommendations

Diagnosis

• Use TNM 2017 classification for tumour staging and 2016 WHO classification for histopathology.
• Assess tumour size via CT or MRI for maximal diameter measurement.
• Monitor for local and distant recurrence through medical record review at 5 and 10 years post-diagnosis.

Management

• Partial nephrectomy or ablative therapy are curative-intent treatments for localized nmRCC.
• Repeated ablation is recommended after ablative therapy failure.
• Surgical removal of local recurrence may provide durable tumour control if negative margins are achieved, despite complication risks.

Monitoring & Follow-up

• Follow patients for at least 5 years post-treatment for recurrence surveillance.
• Use competing risks Cox regression models to evaluate recurrence and mortality outcomes.
• Monitor for local recurrence primarily within 20–36 months after treatment.

Risks

• Higher risk of local recurrence with larger tumour size, multifocality, incomplete treatment, and vascular or tissue invasion.
• Complications may occur with surgical salvage of local recurrence.
• Older age and longer waiting times for treatment observed in ablative therapy patients.

Patient & Prescribing Data

2751 tumours in 2701 unique nmRCC patients treated with partial nephrectomy or ablative therapy

Ablative therapy patients were older, had smaller tumours, longer treatment wait times, and higher incidental findings compared to partial nephrectomy patients; local and distant recurrence rates differ between treatments.

Clinical Best Practices

• Consider tumour size, stage, and histopathology when selecting nephron-sparing treatment modality.
• Implement rigorous follow-up protocols to detect local and distant recurrences early.
• Use repeated ablation as first salvage option after ablative therapy failure, with surgical salvage considered for local recurrence with achievable negative margins.
• Adjust treatment decisions based on patient age, tumour characteristics, and risk factors for recurrence.

References

• National Swedish Kidney Cancer Register (NSKCR)
• TNM Classification of Malignant Tumours, 8th Edition, 2017
• WHO Classification of Tumours of the Urinary System and Male Genital Organs, 2016